Theravance Biopharma Past Earnings Performance

Past criteria checks 4/6

Theravance Biopharma has been growing earnings at an average annual rate of 63.7%, while the Pharmaceuticals industry saw earnings growing at 10.9% annually. Revenues have been growing at an average rate of 14.1% per year. Theravance Biopharma's return on equity is 18.6%, and it has net margins of 51.6%.

Key information

63.66%

Earnings growth rate

60.95%

EPS growth rate

Pharmaceuticals Industry Growth	5.95%
Revenue growth rate	14.06%
Return on equity	18.57%
Net Margin	51.58%
Last Earnings Update	30 Jun 2026

Recent past performance updates

No updates

Recent updates

No updates

Revenue & Expenses Breakdown

How Theravance Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:TBPH Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses
30 Jun 26	104	54	69
31 Mar 26	110	115	73
31 Dec 25	107	106	74
30 Sep 25	80	29	74
30 Jun 25	77	13	72
31 Mar 25	65	-58	71
31 Dec 24	64	-56	69
30 Sep 24	63	-49	67
30 Jun 24	62	-46	66
31 Mar 24	62	-45	68
31 Dec 23	57	-55	70
30 Sep 23	55	-61	71
30 Jun 23	51	-68	71
31 Mar 23	49	-75	68
31 Dec 22	51	-93	67
30 Sep 22	52	-136	72
30 Jun 22	52	-196	77
31 Mar 22	54	-226	87
31 Dec 21	55	-265	99
30 Sep 21	59	-266	108
30 Jun 21	64	-264	114
31 Mar 21	66	-275	113
31 Dec 20	72	-295	109
30 Sep 20	83	-285	112
30 Jun 20	77	-270	110
31 Mar 20	88	-247	107
31 Dec 19	73	-236	106
30 Sep 19	60	-221	98
30 Jun 19	60	-222	95
31 Mar 19	57	-223	98
31 Dec 18	60	-216	97
30 Sep 18	49	-252	101
30 Jun 18	41	-260	100
31 Mar 18	21	-285	100
31 Dec 17	15	-285	96
30 Sep 17	17	-266	86
30 Jun 17	31	-233	86
31 Mar 17	33	-214	82
31 Dec 16	49	-191	85
30 Sep 16	47	-168	88
30 Jun 16	38	-182	91
31 Mar 16	40	-182	92
31 Dec 15	42	-182	90
30 Sep 15	40	-202	88

Quality Earnings: TBPH has a large one-off gain of $111.4M impacting its last 12 months of financial results to 30th June, 2026.

Growing Profit Margin: TBPH's current net profit margins (51.6%) are higher than last year (16.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: TBPH has become profitable over the past 5 years, growing earnings by 63.7% per year.

Accelerating Growth: TBPH's earnings growth over the past year (312.9%) exceeds its 5-year average (63.7% per year).

Earnings vs Industry: TBPH earnings growth over the past year (312.9%) exceeded the Pharmaceuticals industry 1%.

Return on Equity

High ROE: TBPH's Return on Equity (18.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/14 03:16
End of Day Share Price	2026/08/13 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Theravance Biopharma, Inc. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brian Skorney	Baird
Tazeen Ahmad	BofA Global Research
Mayank Mamtani	B. Riley Securities, Inc.